AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36195927 — intervention group
Group type: COMPARATOR
Intervention: Non-active placebo paste
Number of subjects: 24
Study 34353985 — intervention group
Group type: EXPERIMENTAL
Intervention: Layered closure
Number of subjects: 268
Study 34353985 — intervention group
Group type: COMPARATOR
Intervention: Mass closure
Number of subjects: 268
Study 33094825 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of being monitored (awareness group)
Number of subjects: 55
Study 33094825 — intervention group
Group type: COMPARATOR
Intervention: No awareness of being monitored (no awareness group)
Number of subjects: 55
Study 33094825 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of being monitored in people with diabetes
Number of subjects: 55
Study 33094825 — intervention group
Group type: COMPARATOR
Intervention: No awareness of being monitored in people with diabetes
Number of subjects: 55
Study 33896243 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral approach (ALA)
Number of subjects: 48
Study 33896243 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach (PA)
Number of subjects: 48
Study 33419686 — intervention group
Group type: EXPERIMENTAL
Intervention: EZ-Blocker
Number of subjects: 163
Study 33419686 — intervention group
Group type: COMPARATOR
Intervention: DLT
Number of subjects: 163
Study 34291481 — intervention group
Group type: EXPERIMENTAL
Intervention: DDXC+ (differential diagnosis checklist containing the correct diagnosis)
Number of subjects: 90
Study 34291481 — intervention group
Group type: EXPERIMENTAL
Intervention: DDXC- (differential diagnosis checklist not containing the correct diagnosis)
Number of subjects: 90
Study 34291481 — intervention group
Group type: COMPARATOR
Intervention: Control (no checklist)
Number of subjects: 90
Study 34291481 — intervention group
Group type: EXPERIMENTAL
Intervention: DDXC+
Number of subjects: 90
Study 34291481 — intervention group
Group type: EXPERIMENTAL
Intervention: DDXC-
Number of subjects: 90
Study 34291481 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 32195961 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied to the soft palate and tongue base, 8 seconds per point, twice a week for 2 months using Therapy Plus NS 13678 Laser.
Number of subjects: 0
Study 32195961 — intervention group
Group type: COMPARATOR
Intervention: Placebo (device turned off) with similar application protocol as LLLT group.
Number of subjects: 0
Study 36463874 — intervention group
Group type: EXPERIMENTAL
Intervention: Best paper selection process
Number of subjects: 1096
Study 36463874 — intervention group
Group type: EXPERIMENTAL
Intervention: Operational and scalable framework for generating EHR datasets
Number of subjects: 1096
Study 36463874 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure and scalable platform for preprocessing biomedical data
Number of subjects: 1096
Study 36463874 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of care and research activities with REDCap CDIS module
Number of subjects: 1096
Study 34398091 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Number of subjects: 100
Study 34398091 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 100
Study 32780773 — intervention group
Group type: EXPERIMENTAL
Intervention: Affectometer‐2 (AFM‐2)
Number of subjects: 444
Study 32780773 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic Thought Questionnaire‐Positive (ATQ‐P)
Number of subjects: 444
Study 32780773 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized Self‐Efficacy Scale (GSEs)
Number of subjects: 444
Study 32780773 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire‐9 (PHQ‐9)
Number of subjects: 444
Study 32780773 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with Life Scale (SWLS)
Number of subjects: 444
Study 34370681 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatments for oral mucositis as per Mucositis Guidelines
Number of subjects: 0
Study 34370681 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews of randomized controlled trials (RCT)
Number of subjects: 0
Study 33439563 — intervention group
Group type: EXPERIMENTAL
Intervention: Teethmate Desensitizer
Number of subjects: 50
Study 33439563 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond 2
Number of subjects: 50
Study 33439563 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 50
Study 35717342 — intervention group
Group type: EXPERIMENTAL
Intervention: NaPB 4.8 g/m²/day
Number of subjects: 18
Study 35717342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 33336219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 2.5 mg
Number of subjects: 62
Study 33336219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg
Number of subjects: 62
Study 33336219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Number of subjects: 62
Study 33336219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 15 mg
Number of subjects: 62
Study 33336219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 32435054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 0
Study 32435054 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 0
Study 32435054 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hoc analysis excluding non-adherent participants
Number of subjects: 0
Study 32435054 — intervention group
Group type: EXPERIMENTAL
Intervention: Reanalysis with control for confounding
Number of subjects: 0
Study 32435054 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analyses
Number of subjects: 0
Study 36056443 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropulse laser combined with ranibizumab
Number of subjects: 0
Study 36056443 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab monotherapy
Number of subjects: 0
Study 34401595 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Behavioral Health Program (CBHP)
Number of subjects: 0
Study 34401595 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies provided to all practices
Number of subjects: 0
Study 34401595 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic analyses
Number of subjects: 0
Study 36412916 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy (three 30-minute sessions weekly during chemotherapy)
Number of subjects: 30
Study 36412916 — intervention group
Group type: COMPARATOR
Intervention: Control (standard breast cancer treatment without yoga)
Number of subjects: 30
Study 33045913 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol + micronised progesterone
Number of subjects: 67
Study 33045913 — intervention group
Group type: COMPARATOR
Intervention: Transdermal oestradiol + medroxyprogesterone acetate
Number of subjects: 67
Study 36203214 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity endurance exercise (4 days/week for 30 min per session at 80–85% maximum heart rate)
Number of subjects: 370
Study 36203214 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity endurance exercise (4 days/week for 30 min per session at 60–65% maximum heart rate)
Number of subjects: 370
Study 36203214 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity endurance exercise
Number of subjects: 370
Study 36203214 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity endurance exercise
Number of subjects: 370
Study 33516293 — intervention group
Group type: EXPERIMENTAL
Intervention: SIIPL-PCV
Number of subjects: 2250
Study 33516293 — intervention group
Group type: COMPARATOR
Intervention: PHiD-CV
Number of subjects: 2250
Study 32629446 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed by cetuximab and RT (IBRT)
Number of subjects: 236
Study 32629446 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin concurrent with RT (CRT)
Number of subjects: 236
Study 34318979 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Helping Alliance Questionnaire (HAq‐II) completed by patients and therapists after interventions.
Number of subjects: 285
Study 34318979 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis (CFA) used to investigate the internal structure of HAq‐II.
Number of subjects: 285
Study 34318979 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical tests including t‐test for independent samples, ANOVA, and Pearson's correlation coefficient.
Number of subjects: 285
Study 34077270 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1) 3.6 mg/kg IV every 3 weeks for 17 cycles
Number of subjects: 497
Study 34077270 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus trastuzumab (TH) 80 mg/m2 IV with H once every week for 12 weeks followed by H for 39 weeks
Number of subjects: 497
Study 34077270 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Number of subjects: 497
Study 33581997 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice treatment with water resistance therapy (WRT) plus vocal hygiene program (n = 12)
Number of subjects: 24
Study 33581997 — intervention group
Group type: COMPARATOR
Intervention: Vocal hygiene program only (n = 12)
Number of subjects: 24
Study 33649930 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg doxorubicin (group A)
Number of subjects: 28
Study 33649930 — intervention group
Group type: COMPARATOR
Intervention: 100 mg doxorubicin (group B)
Number of subjects: 28
Study 33057807 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab followed by denosumab
Number of subjects: 187
Study 33057807 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by denosumab
Number of subjects: 187
Study 32106110 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned media (CM) from acute intense exercise
Number of subjects: 0
Study 32106110 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioned media (CM) from chronic moderate exercise
Number of subjects: 0
Study 32106110 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant GDF15 protein
Number of subjects: 0
Study 32106110 — intervention group
Group type: COMPARATOR
Intervention: Blocking GDF15 with a neutralizing antibody
Number of subjects: 0
Study 35256489 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flow anesthesia (1 L.min‐1 after initial 6 L.min‐1 for 10 minutes)
Number of subjects: 99
Study 35256489 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-flow anesthesia (2 L.min‐1)
Number of subjects: 99
Study 35256489 — intervention group
Group type: COMPARATOR
Intervention: High-flow anesthesia (4 L.min‐1)
Number of subjects: 99
Study 33594772 — intervention group
Group type: EXPERIMENTAL
Intervention: GI-6301 vaccine (80 × 10^7 yeast cells)
Number of subjects: 24
Study 33594772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32268771 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D1: perineural administration of dexmedetomidine 0.5 µg/kg + intercostal nerve block with 0.5% ropivacaine
Number of subjects: 150
Study 32268771 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D2: intravenous infusion of dexmedetomidine 0.5 µg/kg + intercostal nerve block with 0.5% ropivacaine
Number of subjects: 150
Study 32268771 — intervention group
Group type: COMPARATOR
Intervention: Group R: intercostal nerve block with 0.5% ropivacaine
Number of subjects: 150
Study 34617341 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-level (IL) connection
Number of subjects: 50
Study 34617341 — intervention group
Group type: COMPARATOR
Intervention: Abutment-level (AL) connection
Number of subjects: 50
Study 34617341 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 33974178 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite accessions
Number of subjects: 8
Study 33974178 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsolete accessions
Number of subjects: 8
Study 33974178 — intervention group
Group type: EXPERIMENTAL
Intervention: All accessions
Number of subjects: 8
Study 33974178 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 8
Study 35346331 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical dry needling
Number of subjects: 92
Study 35346331 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (ischaemic compression, analytic stretching, postural education training)
Number of subjects: 92
Study 33544240 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg once daily for 40 weeks
Number of subjects: 97
Study 33544240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 35710320 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine (active treatment), n=53, geometric mean=6.33 pg/mL
Number of subjects: 126
Study 35710320 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment, n=73, geometric mean=7.00 pg/mL
Number of subjects: 126
Study 35710320 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine (active treatment)
Number of subjects: 126
Study 35710320 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 126
Study 32813171 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel tonsillectomy
Number of subjects: 82
Study 32813171 — intervention group
Group type: COMPARATOR
Intervention: Coblation tonsillectomy
Number of subjects: 82
Study 32813171 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 82
Study 35452395 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) A, 4-, 2-, and 1-min intervals; 80-90% VO2peak, n=8
Number of subjects: 26
Study 35452395 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) B, 4x4 min intervals; 80-90% VO2peak, n=8
Number of subjects: 26
Study 35452395 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Training (MICT), 40 min; 50-60% VO2peak, n=8
Number of subjects: 26
Study 33249609 — intervention group
Group type: EXPERIMENTAL
Intervention: Full prophylaxis (palivizumab doses for each month of RSV exposure)
Number of subjects: 1083
Study 33249609 — intervention group
Group type: COMPARATOR
Intervention: Partial prophylaxis
Number of subjects: 1083
Study 35038601 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine treatment
Number of subjects: 4159
Study 35038601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4159
Study 33783363 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional media (newspaper and radio)
Number of subjects: 200
Study 33783363 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook advertisements
Number of subjects: 200
Study 33783363 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpaid advertisements (posters and websites)
Number of subjects: 200
Study 33783363 — intervention group
Group type: COMPARATOR
Intervention: Referral by health care providers or word of mouth
Number of subjects: 200
Study 33783363 — intervention group
Group type: COMPARATOR
Intervention: Media (local newspaper stories and radio interviews)
Number of subjects: 200
Study 32679602 — intervention group
Group type: EXPERIMENTAL
Intervention: Purastat
Number of subjects: 101
Study 32679602 — intervention group
Group type: COMPARATOR
Intervention: Control (diathermy)
Number of subjects: 101
Study 33220054 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb lymphoedema (podoconiosis and other causes)
Number of subjects: 1143
Study 33220054 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 1143
Study 33220054 — intervention group
Group type: EXPERIMENTAL
Intervention: PHQ-9 score
Number of subjects: 1143
Study 33251697 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine (IGlu)
Number of subjects: 0
Study 33251697 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGla)
Number of subjects: 0
Study 33046127 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hyperoxemia (PaO2 > 150 mmHg)
Number of subjects: 5912
Study 33046127 — intervention group
Group type: COMPARATOR
Intervention: Normoxemia (150 > PaO2 ≥ 60 mmHg)
Number of subjects: 5912
Study 36040559 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-17A
Number of subjects: 14
Study 36040559 — intervention group
Group type: EXPERIMENTAL
Intervention: sIL-2R
Number of subjects: 14
Study 36040559 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum amyloid A
Number of subjects: 14
Study 36040559 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 14
Study 36040559 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10
Number of subjects: 14
Study 36040559 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-α
Number of subjects: 14
Study 36040559 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte chemoattractant protein-1
Number of subjects: 14
Study 36040559 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 14
Study 32471910 — intervention group
Group type: EXPERIMENTAL
Intervention: CLC (Control‐IQ)
Number of subjects: 109
Study 32471910 — intervention group
Group type: COMPARATOR
Intervention: PLGS (Basal‐IQ)
Number of subjects: 109
Study 35764956 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy plus PD‐1 antibody with preoperative chemoradiation (Arm A)
Number of subjects: 0
Study 35764956 — intervention group
Group type: COMPARATOR
Intervention: Perioperative chemotherapy plus PD‐1 antibody without preoperative chemoradiation (Arm B)
Number of subjects: 0
Study 33429756 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomimetic double-layer biofilm stent group
Number of subjects: 0
Study 33429756 — intervention group
Group type: COMPARATOR
Intervention: Non-bionic dual-layer biofilm stent group
Number of subjects: 0
Study 32223389 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater income
Number of subjects: 0
Study 32223389 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational attainment
Number of subjects: 0
Study 35468489 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised preformed foot orthoses (FOs)
Number of subjects: 66
Study 35468489 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 66
Study 34525285 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi polysaccharide typhoid conjugate vaccine (Vi-TCV)
Number of subjects: 28130
Study 34525285 — intervention group
Group type: COMPARATOR
Intervention: Meningococcal capsular group A conjugate (MenA) vaccine
Number of subjects: 28130
Study 32926834 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administered Na-GST-1 and Na-APR-1 (M74) vaccines (30 μg or 100 μg of each), adjuvanted with Alhydrogel and glucopyranosyl lipid A, administered intramuscularly on days 0, 28, and 180.
Number of subjects: 32
Study 32926834 — intervention group
Group type: COMPARATOR
Intervention: Control group received hepatitis B vaccine plus saline, administered intramuscularly on days 0, 28, and 180.
Number of subjects: 32
Study 33264544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 307
Study 33264544 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (5-fluorouracil-based therapy with or without bevacizumab or cetuximab every 2 weeks)
Number of subjects: 307
Study 33264544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 307
Study 33264544 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 307
Study 33460574 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy
Number of subjects: 5760
Study 33460574 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 5760
Study 32101996 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Number of subjects: 4388
Study 34114288 — intervention group
Group type: EXPERIMENTAL
Intervention: Salutogenesis-based home care (1 time per week for 8 weeks)
Number of subjects: 73
Study 34114288 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 73
Study 33143212 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaseolus Vulgaris (PV) consumption, 250 g as an extract thrice weekly for 6 weeks
Number of subjects: 60
Study 32698634 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphala (1 g standardized as 91.82 ± 0.5 mg gallic acid, administered BID)
Number of subjects: 80
Study 32698634 — intervention group
Group type: COMPARATOR
Intervention: Placebo (wheat flour, administered BID)
Number of subjects: 80
Study 32698634 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphala
Number of subjects: 80
Study 32698634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33900931 — intervention group
Group type: EXPERIMENTAL
Intervention: cCBT + treatment as usual (TAU)
Number of subjects: 252
Study 33900931 — intervention group
Group type: COMPARATOR
Intervention: TAU without cCBT
Number of subjects: 252
Study 34037699 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic aligners (OAs)
Number of subjects: 40
Study 34037699 — intervention group
Group type: COMPARATOR
Intervention: Conventional fixed appliances
Number of subjects: 40
Study 34037699 — intervention group
Group type: COMPARATOR
Intervention: Both groups (OAs and fixed appliances)
Number of subjects: 40
Study 33845941 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdiscectomy
Number of subjects: 163
Study 33845941 — intervention group
Group type: COMPARATOR
Intervention: Transforaminal epidural steroid injection
Number of subjects: 163
Study 36174592 — intervention group
Group type: EXPERIMENTAL
Intervention: PBO LLINs (PermaNet 3.0 or Olyset Plus)
Number of subjects: 6492
Study 36174592 — intervention group
Group type: COMPARATOR
Intervention: Non-PBO LLINs (PermaNet 2.0 or Olyset Net)
Number of subjects: 6492
Study 36174592 — intervention group
Group type: EXPERIMENTAL
Intervention: PBO LLINs
Number of subjects: 6492
Study 36174592 — intervention group
Group type: COMPARATOR
Intervention: Non-PBO LLINs
Number of subjects: 6492
Study 33115285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg/2 weeks after 160 mg initial dose)
Number of subjects: 54
Study 33115285 — intervention group
Group type: COMPARATOR
Intervention: Secukinumab (300 mg subcutaneous injection at Weeks 0, 1, 2, 3, and 4 then every 4 weeks)
Number of subjects: 54